Tobii Wins Design Deal to Power Early Autism Screening Tool in India

Tobii AB ( (SE:TOBII) ) has provided an announcement.

Tobii has secured a design win to supply its Tobii Eye Tracker 5L to Butterfly Learnings for integration into Get Set Early, an eye tracking–based autism spectrum disorder screening tool for children as young as 12 months. Developed from patented, scientifically validated research by UC San Diego’s Dr. Karen Pierce and now clinically approved in India, the tool offers non-invasive, objective biomarkers to support earlier autism detection and more effective therapy.

The rollout of Get Set Early across clinics in India positions Tobii more firmly in the digital health and neurodevelopmental diagnostics market, underscoring the commercial potential of its eye tracking platform beyond traditional research and gaming applications. Collaboration with Butterfly Learnings and local reseller Tiden Technologies highlights Tobii’s strategy of partnering with specialist healthcare and neuroscience players to scale clinically approved, technology-driven screening solutions in high-growth markets and potentially beyond India.

The most recent analyst rating on (SE:TOBII) stock is a Sell with a SEK1.50 price target. To see the full list of analyst forecasts on Tobii AB stock, see the SE:TOBII Stock Forecast page.

More about Tobii AB

Tobii AB is a Sweden-based global leader in eye tracking and a pioneer in attention computing, providing hardware and software that interpret human gaze and intent. Its technologies are used across sectors including healthcare, behavioral research, education and training, gaming, extended reality, and automotive, serving thousands of enterprises, universities, and research institutes worldwide.

Average Trading Volume: 2,327,495

Technical Sentiment Signal: Strong Sell

Current Market Cap: SEK344.2M

For a thorough assessment of TOBII stock, go to TipRanks’ Stock Analysis page.